The initial Phase 3 clinical trial programme involving TauRx’s second-generation tau aggregation inhibitor, LMTX®, comprised two clinical trials (TRX-005 and TRX-015) in Alzheimer’s disease and a further trial (TRX-007) in the neurodegenerative orphan indication behavioural variant frontotemporal dementia (bvFTD). These three studies completed in 2016. The trials failed to meet the primary endpoints for which they were originally designed, but demonstrated promising results which warrant further investigation. TauRx therefore plans to initiate additional clinical studies specifically designed to build on the encouraging data emerging from these Phase 3 trials.
Future research will focus on two areas of particular interest:
An abstract from the first of TauRx's two Phase 3 trials in Alzheimer’s disease in mild and moderate patients was presented at the 2016 Alzheimer's Association International Conference (AAIC) in Toronto, Canada on 27th July 2016 and results were published in The Lancet in November 2016.
An abstract from the second Phase 3 trial in Alzheimer’s disease in mild patients only was presented at the 2016 Clinical Trials in Alzheimer’s Disease (CTAD) in San Diego, USA on 8th December. Publication is expected in the first half of 2017.
An abstract from the trial in bvFTD was presented at the 10th International Conference on Frontotemporal Dementias (ICFTD), 31 August-2 September 2016.
To read an interview concerning the Phase 3 results with TauRx’s Executive Chairman and co-Founder, Professor Claude Wischik, please follow this link.